LivaNova (NASDAQ:LIVN) Price Target Raised to $90.00

LivaNova (NASDAQ:LIVN) had its price objective boosted by Mizuho from $85.00 to $90.00 in a research note published on Thursday morning, MarketBeat Ratings reports. They currently have an outperform rating on the stock.

Several other research analysts have also recently weighed in on LIVN. Piper Sandler reissued an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a research report on Thursday, February 19th. Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday, February 25th. Robert W. Baird cut their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday. Barclays boosted their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $77.22.

LivaNova Stock Up 1.3%

LIVN stock opened at $71.86 on Thursday. The stock’s fifty day simple moving average is $64.01 and its two-hundred day simple moving average is $62.15. The company has a current ratio of 1.33, a quick ratio of 1.16 and a debt-to-equity ratio of 0.24. LivaNova has a 1-year low of $41.01 and a 1-year high of $72.51. The stock has a market cap of $3.95 billion, a P/E ratio of 36.85 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter in the previous year, the firm earned $0.88 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Analysts expect that LivaNova will post 3.68 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares during the last quarter. State of Wyoming bought a new stake in shares of LivaNova during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC raised its stake in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the period. Quarry LP bought a new stake in shares of LivaNova during the 3rd quarter valued at $36,000. Finally, UMB Bank n.a. raised its stake in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after purchasing an additional 306 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.